Combined negative and positive selection of mobilized CD34+ blood cells

We tested four negative and two positive selection methods for separation of CD34+ cells from mobilized blood cells, and analysed fold‐enrichment, purity and recovery of CD34+ cells after selection procedures. The elimination of mature CD34− cells was achieved by adhesion to nylon‐wool fibre (5.9 ± 1.0 mean fold‐enrichment and 65.2 ± 2.3 mean recovery of CD34+ cells). Standard or modified Ficoll‐Hypaque and Percoll density gradients, as well as phagocytosis with magnetic beads, were less effective in eliminating CD34− cells, both purity and fold‐enrichment of CD34+ cells being lower than those obtained with separation by nylon‐wool. Both positive selection methods tested, Ceprate and MiniMacs System, generated highly purified CD34+ cell populations ranging from 80% to 90%. The recovery of CD34+ cells was optimal with MiniMacs (77.9±3.6) and low with Ceprate (28.8±2.8). Based on these results, in two large‐scale experiments we combined nylon‐wool fibre and MiniMacs System in a two‐step separation procedure obtaining a 36.9±2.6 mean fold‐enrichment and a 50.5±0.3 mean recovery of CD34+ cells. In this way we achieved optimal enrichment and recovery of CD34+ cells, with a substantial saving of cost compared to either selection method alone.

[1]  P. Greenberg,et al.  Enrichment of bone marrow and blood progenitor (CD34+) cells by density gradients with sufficient yields for transplantation. , 1995, Experimental hematology.

[2]  A. Nienhuis,et al.  Retrovirally marked CD34-enriched peripheral blood and bone marrow cells contribute to long-term engraftment after autologous transplantation. , 1995, Blood.

[3]  G. Bonadonna,et al.  Large-scale enrichment of mobilized CD34+ peripheral blood hematopoietic progenitors by removal of nylon wool-adherent mature cells. , 1994, Bone marrow transplantation.

[4]  E. Wunders Hematopoietic stem cells : the Mulhouse manual , 1994 .

[5]  E. Shpall,et al.  Transplantation of enriched CD34-positive autologous marrow into breast cancer patients following high-dose chemotherapy: influence of CD34-positive peripheral-blood progenitors and growth factors on engraftment. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  R. Collins CD34+ selected cells in clinical transplantation , 1994, Stem cells.

[7]  I. Weissman,et al.  Isolation of a candidate human hematopoietic stem-cell population. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[8]  G. Bonadonna,et al.  Human peripheral blood hematopoietic progenitors are optimal targets of retroviral-mediated gene transfer. , 1992, Blood.

[9]  I. Bernstein,et al.  Engraftment after infusion of CD34+ marrow cells in patients with breast cancer or neuroblastoma. , 1991, Blood.

[10]  P. Lansdorp,et al.  Flow cytometry for clinical estimation of circulating hematopoietic progenitors for autologous transplantation in cancer patients. , 1991, Blood.

[11]  S. Siena,et al.  Large-scale collection of circulating haematopoietic progenitors in cancer patients treated with high-dose cyclophosphamide and recombinant human GM-CSF. , 1990, European journal of cancer.

[12]  Andreas Radbruch,et al.  High gradient magnetic cell separation with MACS. , 1990, Cytometry.

[13]  S. Siena,et al.  High Sensitivity and Specificity Assay for Detection of Leukemia/Lymphoma Cells in Human Bone Marrow a , 1987, Annals of the New York Academy of Sciences.

[14]  C. Civin,et al.  Cell surface antigens on human marrow cells: dissection of hematopoietic development using monoclonal antibodies and multiparameter flow cytometry. , 1987, International journal of cell cloning.

[15]  W. Bensinger,et al.  Positive selection of viable cell populations using avidin-biotin immunoadsorption. , 1986, Journal of immunological methods.

[16]  M. Fackler,et al.  Antigenic analysis of hematopoiesis. III. A hematopoietic progenitor cell surface antigen defined by a monoclonal antibody raised against KG-1a cells. , 1984, Journal of immunology.